United States Patent 8,735,375: Scope, Claims, Expiration, and Ingenol Angelate Patent Landscape

U.S. Patent No. 8,735,375 protects methods of topically treating skin cancer and actinic keratosis with a low-concentration, highly purified ingenol angelate formulation at an acidic pH. The patent is narrower than a basic compound patent because infringement requires practicing a treatment method with specified concentration, isoform purity, pH, route of administration, and disease conditions.

The commercial relevance of the patent is tied to ingenol mebutate, also known as ingenol-3-angelate and marketed as Picato. Picato was approved by the U.S. Food and Drug Administration for actinic keratosis, not for the skin-cancer indications recited in the patent claims.[1] FDA later identified serious safety concerns and the product was withdrawn from the U.S. market.[2]

What does U.S. Patent 8,735,375 cover?

The patent covers topical administration of ingenol angelate formulations that satisfy four core limitations:

The formulation is administered topically to skin or a skin lesion.
Ingenol angelate is present at approximately 0.001% to 0.15% weight/weight.
At least approximately 97.5% of the ingenol angelate is ingenol-3-angelate, identified in the claims as isoform “b.”
The formulation has a pH below 4.

The independent claims are method claims rather than composition claims. A party does not infringe merely by manufacturing or possessing an acidic ingenol angelate gel. The asserted conduct must involve administering the formulation to a subject for one of the claimed conditions.

Claim architecture

Claim group	Independent claim	Covered condition	Key formulation limitations
Skin cancer treatment	1	Skin cancer generally	0.001%-0.15% w/w; at least 97.5% ingenol-3-angelate; pH below 4
Cancerous skin lesion treatment	13	SCC, BCC, malignant melanoma, or actinic keratosis	Same concentration, purity, and pH limitations
pH subranges	2-4 and 14-16	Dependent on claims 1 or 13	pH about 3.5 or less; about 3.0; or 2.5 to below 4.0
Disease-specific claims	5-7, 9-12, 17-24	SCC, BCC, melanoma	Retain the parent formulation limitations
Actinic keratosis	25-26	Actinic keratosis	Covered under claim 13 and its pH-specific dependent claim

The patent therefore has two principal independent claim families. Claim 1 is directed to treating “skin cancer.” Claim 13 is broader in disease enumeration because it expressly includes actinic keratosis, while also covering squamous cell carcinoma, basal cell carcinoma, and malignant melanoma.[3]

How broad are the claims of U.S. Patent 8,735,375?

The claims are technically narrow but therapeutically broad. The disease language reaches multiple skin malignancies, but the formulation limitations substantially constrain the claim scope.

Formulation limitations

The claimed concentration range is approximately 0.001% to 0.15% w/w. This range encompasses concentrations associated with topical ingenol products, including low-strength formulations used for actinic keratosis.

The purity limitation is central. At least 97.5% of the ingenol angelate must be ingenol-3-angelate, or isoform “b.” A formulation containing a materially greater proportion of another ingenol angelate isoform may fall outside the literal claim scope, depending on the composition and analytical evidence.

The pH limitation is also material. The independent claims require a pH below 4. Dependent claims narrow the pH to:

About 3.5 or less;
About 3.0; or
About 2.5 to less than 4.0.

A formulation with a pH of 4.0 or higher does not satisfy the literal “less than 4” limitation in the independent claims. A formulation with a pH below 2.5 may satisfy the independent claim but would not fall within dependent claims 4 or 16.

Delivery-system limitation

The claims require topical administration. They do not expressly require a gel in the independent claims. Gel formulations are covered only by dependent claims 8, 12, 20, and 24.

This distinction matters in enforcement. A cream, ointment, lotion, foam, solution, or other topical dosage form may potentially fall within an independent claim if it satisfies the concentration, isoform purity, pH, and disease limitations. It would not satisfy the separate gel limitation unless it is legally characterized as a gel.

Disease limitations

The patent expressly recites:

Squamous cell carcinoma;
Basal cell carcinoma;
Malignant melanoma; and
Actinic keratosis.

Claim 1 uses the broader phrase “skin cancer,” while claim 13 uses a closed list introduced by “selected from the group consisting of.” The closed-list language creates a potential scope difference. A cancerous skin condition not included in that list may not fall within claim 13, although it could still be relevant to claim 1 if it qualifies as skin cancer.

Which claims are strongest from an enforcement perspective?

Claims 1 and 13 are the principal enforcement claims because they are independent. The dependent claims add useful fallback positions but are narrower.

Claim 1

Claim 1 has a broad disease limitation but requires the full formulation profile. It is potentially useful against a topical product used for a skin-cancer indication where the product contains highly purified ingenol-3-angelate at a concentration within the claimed range and has a pH below 4.

Claim 13

Claim 13 is commercially important because it expressly includes actinic keratosis, the indication for which Picato received FDA approval. It may be easier to map against an approved or generic product labeled for actinic keratosis than claim 1, although the closed disease list and formulation limitations remain.

Dependent pH claims

Claims 2-4 and 14-16 create narrower positions around acidic formulations. Their practical value depends on the accuracy and reproducibility of pH testing. pH can vary with temperature, buffering system, sampling method, storage, and manufacturing lot.

Dependent gel claims

The gel claims may provide an additional theory of infringement against a product whose dosage form is clearly a gel. They are less useful against non-gel topical formulations, even if those formulations otherwise satisfy the independent claims.

What patent protects Picato and ingenol mebutate?

U.S. Patent 8,735,375 is one patent in the broader ingenol mebutate and ingenol angelate estate. Its claims are directed to treatment methods using a defined formulation. It is not a basic chemical compound claim covering every form or use of ingenol mebutate.

The broader estate can be divided into several patent categories:

Patent category	Typical protected subject matter	Relevance to generic entry
Compound patents	Ingenol derivatives, ester forms, or specific chemical entities	May block active-ingredient manufacture or sale
Purity and isoform patents	Predominance of ingenol-3-angelate or defined stereochemical forms	Can affect API sourcing and analytical design
Formulation patents	Gels, vehicles, stabilizers, buffers, and pH-controlled compositions	Can affect ANDA formulation design
Method-of-treatment patents	Treatment of actinic keratosis, skin cancer, or other lesions	Can create labeling and induced-infringement issues
Manufacturing patents	Extraction, purification, isomer control, or synthetic production	May increase API development risk
Regulatory patents	Patents listed for an approved drug product in the Orange Book	Can trigger Paragraph IV litigation

The existence of U.S. Patent 8,735,375 does not establish that all related patents remain enforceable. Patent term, terminal disclaimers, patent-term adjustment, maintenance fees, post-grant proceedings, and Orange Book listing status must be assessed patent by patent.[4]

When does U.S. Patent 8,735,375 expire?

The statutory term for a modern U.S. utility patent is generally 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory corrections.[4]

The patent’s enforceable expiration date should therefore be taken from the official patent record and any associated term adjustment or extension data. The grant date, May 27, 2014, does not determine the expiration date.[3]

For commercial planning, the critical distinction is between:

The patent’s nominal 20-year term;
Any patent-term adjustment added for USPTO examination delay;
Any patent-term extension under 35 U.S.C. § 156;
Any terminal disclaimer tying the patent to an earlier-expiring patent; and
Whether maintenance fees were paid.

Because the claims are method claims, expiration eliminates patent protection under this patent even if the product remains approved or commercially recognizable. Regulatory withdrawal does not itself terminate patent rights before the statutory expiration date.

What is the Orange Book status of U.S. Patent 8,735,375?

A patent is relevant to the Orange Book only if it is submitted by the NDA holder and accepted by FDA for listing against the approved drug product. The patent number alone does not establish Orange Book listing.

For Picato, the relevant regulatory product was ingenol mebutate gel under NDA 202833. FDA approved Picato in January 2012 for actinic keratosis.[1] FDA later recorded the product’s withdrawal after safety concerns involving skin tumors and other adverse events.[2]

The patent’s claim structure creates a potential Orange Book issue because:

Claim 13 expressly covers actinic keratosis;
The claimed concentration range overlaps topical ingenol mebutate products;
The pH limitation may correspond to the approved formulation; and
The claims are directed to a method of using the approved active ingredient.

An ANDA applicant challenging a listed patent could use a Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed. A Section VIII statement could be relevant if the applicant carved out a patented method of use from its labeling. The availability of a carve-out would depend on the scope of the listed claims and the proposed label.

Which companies could challenge the patent?

Generic-drug companies developing an ingenol mebutate topical product would be the most likely challengers. Potential challengers would include companies with:

An ANDA strategy for the Picato reference product;
Access to qualified ingenol-3-angelate API;
A formulation that can maintain the required purity and acidic pH;
Analytical capability to distinguish isoform “b” from other angelate forms; and
A commercial rationale for entering a withdrawn or restricted market.

The absence of a currently marketed U.S. reference product materially reduces the immediate commercial incentive for a Paragraph IV challenge. A future applicant would still need to address whether the reference product remains eligible for an ANDA pathway, whether FDA would accept the relevant application, and whether the patent is listed and unexpired at the time of certification.

No biosimilar pathway applies. Ingenol mebutate is a small molecule, not a biologic. The relevant pathway would be an ANDA or, depending on the regulatory facts, a 505(b)(2) application. The competitive risk is therefore generic or hybrid-drug entry rather than biosimilar substitution.

What formulation and manufacturing barriers does the patent create?

The most significant technical barriers are isoform purity and pH control.

Isoform control

The 97.5% threshold requires a manufacturer to demonstrate that the active ingredient is predominantly ingenol-3-angelate. Analytical methods must distinguish the claimed isoform from related ingenol angelate forms and degradation products.

A generic manufacturer could pursue several design strategies:

Use a process producing the same isoform but challenge validity or infringement;
Use a formulation with a different isoform distribution;
Alter the concentration outside 0.001%-0.15% w/w;
Use a pH of 4.0 or higher;
Seek a non-gel dosage form; or
Pursue a label that omits patented uses.

Each design-around carries regulatory and technical consequences. Concentration or pH changes may affect efficacy, stability, tolerability, penetration, and comparability.

Manufacturing and stability

Acidic topical formulations can present stability and packaging issues. Relevant development controls include:

pH drift during storage;
Hydrolysis or degradation of the ester;
Adsorption to packaging;
Uniformity of low-dose API distribution;
Preservation and microbial control;
Lot-to-lot isoform consistency; and
Stability after opening or application.

A product that is outside the literal claim range at release but moves into the claimed range during shelf life can create both regulatory and patent-risk questions.

What litigation and settlement risks exist?

The supplied claim set does not establish a reported infringement action, Paragraph IV case, or settlement involving U.S. Patent 8,735,375. Patent litigation risk would arise if a proposed generic:

References Picato or relies on its clinical and regulatory data;
Uses a formulation within the claimed concentration and pH ranges;
Supplies a product labeled for actinic keratosis or another claimed condition; and
Faces an unexpired, Orange Book-listed patent.

A settlement could involve a license, a delayed-entry date, a formulation restriction, a supply arrangement, or a commitment not to market for particular indications. No settlement terms should be inferred from the patent grant or the later withdrawal of Picato.

How strong is the patent estate?

The patent is strongest against an exact or near-exact copy of the claimed topical formulation used for actinic keratosis or a listed skin cancer. Its strength decreases where the accused product differs in one or more measurable claim elements.

Risk factor	Assessment
Active ingredient overlap	High for ingenol-3-angelate products
Concentration overlap	High if within 0.001%-0.15% w/w
pH overlap	High if below 4; lower at pH 4 or above
Isoform purity overlap	High if at least 97.5% isoform “b”
Dosage-form overlap	High for gels; broader under independent claims
Indication overlap	High for actinic keratosis and listed cancers
Biosimilar exposure	None
Generic exposure	Potentially significant, subject to listing and term
Commercial value after Picato withdrawal	Limited without renewed market demand or a new approved use

The patent is not a complete barrier to all topical ingenol products. It is a formulation-specific method patent with multiple measurable limitations. A credible design-around may be possible, but changing pH, concentration, isoform composition, or indication can create separate regulatory and clinical-development problems.

How does U.S. Patent 8,735,375 compare with competing drug patent estates?

Ingenol mebutate differs from larger dermatology products such as imiquimod, fluorouracil, tirbanibulin, and diclofenac in both patent structure and regulatory risk.

Product	Active ingredient	Main U.S. pathway	Patent risk profile
Picato	Ingenol mebutate	NDA 202833	Method, formulation, purity, and use claims; product withdrawn
Aldara/Zyclara	Imiquimod	NDA products and generics	Older composition and method estate; generic competition established
Efudex and generics	Fluorouracil	NDA and ANDA products	Mature generic market
Klisyri	Tirbanibulin	Newer NDA product	Newer formulation and method estate
Solaraze	Diclofenac sodium	NDA and generic products	Mature topical generic competition

Picato’s commercial position is weaker than that of an actively marketed branded dermatology product because FDA withdrawal removed the immediate U.S. sales base. The remaining patent value depends on redevelopment, relaunch, licensing, or use of the technology in a new product.

What is the revenue exposure associated with this patent?

The direct revenue exposure is limited by Picato’s withdrawal. Before withdrawal, Picato generated commercial value from actinic keratosis treatment, but U.S. revenue after withdrawal is not a dependable basis for forecasting generic-entry damages or licensing value.

Potential value remains in:

A relaunch for an approved indication;
Development of a reformulated ingenol product;
Licensing the isoform-control or acidic topical technology;
Use in a new oncology or dermatology indication; and
Enforcement against an unauthorized product if the patent remains unexpired.

A generic entrant would face a smaller addressable market than it would have faced during active Picato commercialization. That fact reduces the expected value of a Paragraph IV campaign and may make litigation uneconomic unless the applicant has a broader international or pipeline strategy.

Key Takeaways

U.S. Patent 8,735,375 is a method-of-treatment patent for topical ingenol angelate.
The core limitations are 0.001%-0.15% w/w concentration, at least 97.5% ingenol-3-angelate, and pH below 4.
Claim 13 expressly covers actinic keratosis, squamous cell carcinoma, basal cell carcinoma, and malignant melanoma.
The independent claims do not require a gel, although dependent claims separately cover gel formulations.
The patent is potentially relevant to Picato but does not itself establish Orange Book listing.
No biosimilar pathway applies because ingenol mebutate is a small molecule.
Generic risk depends on patent term, listing status, the proposed formulation, labeling, and the commercial viability of a withdrawn product.
The strongest infringement case would involve an exact or near-exact acidic ingenol-3-angelate topical formulation used for actinic keratosis or a listed skin cancer.
The principal design-around variables are isoform purity, concentration, pH, dosage form, and labeling.
Picato’s withdrawal materially reduces present revenue exposure but does not, by itself, eliminate surviving patent rights.

Frequently Asked Questions

Is U.S. Patent 8,735,375 a composition patent?

No. Its asserted independent claims are methods of treating skin disease with a defined topical formulation. The patent does not broadly claim every composition containing ingenol angelate.

Does the patent cover Picato for actinic keratosis?

Claim 13 expressly recites actinic keratosis and includes formulation limitations that may overlap with Picato. Whether a particular Picato formulation falls within the claim depends on its measured concentration, isoform purity, and pH.

Can a generic avoid the patent by using a cream instead of a gel?

Possibly. The independent claims do not require a gel, so changing the dosage form alone may not avoid claims 1 or 13. It may avoid the dependent gel claims, but the other limitations would remain relevant.

Does Picato’s withdrawal invalidate the patent?

No. FDA withdrawal and patent validity are separate legal issues. Withdrawal may reduce commercial value but does not automatically cancel or invalidate a patent.

Is a Paragraph IV challenge available for this patent?

It may be available if the patent is unexpired, listed for the relevant reference product, and implicated by an ANDA applicant’s proposed product. The specific certification depends on FDA listing records and the applicant’s formulation and labeling.

References

U.S. Food and Drug Administration. (2012). FDA approves Picato gel for actinic keratosis. FDA.
U.S. Food and Drug Administration. (2020). FDA warns of increased risk of death from skin cancer with Picato (ingenol mebutate) gel. FDA Drug Safety Communication.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,735,375, methods of treating skin conditions with ingenol angelate.
United States Code. (2023). 35 U.S.C. §§ 154 and 156: Patent term and patent term extension. United States Code.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012		DISCN	Yes	No	8,735,375	⤷ Start Trial				USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS	⤷ Start Trial
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-002	Jan 23, 2012		DISCN	Yes	No	8,735,375	⤷ Start Trial				USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0525680.5	Dec 16, 2005

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1988877	⤷ Start Trial	C300682	Netherlands	⤷ Start Trial
European Patent Office	1988877	⤷ Start Trial	PA2014030	Lithuania	⤷ Start Trial
European Patent Office	1988877	⤷ Start Trial	CA 2014 00042	Denmark	⤷ Start Trial
European Patent Office	1988877	⤷ Start Trial	C20140025 00111	Estonia	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,735,375

Which drugs does patent 8,735,375 protect, and when does it expire?

Summary for Patent: 8,735,375